Department of Nephrology, Molecular Cell Lab for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Center for Peritoneal Dialysis Research, Shanghai, China.
Nephrology (Carlton). 2020 Mar;25(3):248-254. doi: 10.1111/nep.13604. Epub 2019 Jun 20.
Studies showed an increased visceral adipose tissue and peritoneal angiogenesis in peritoneal dialysis (PD) patients. However, the relationship between the visceral adipose expands and peritoneal angiogenesis remains unclear.
Pref-1 (preadipocyte factor-1) recombinant adeno-associated virus (AAV) and control AAV were constructed. Mice were divided into four groups, mice in control and PD group were injected intraperitoneally with PBS, mice in control-AAV-PD were injected intraperitoneally with plaque-forming unit (PFU) control AAV and mice in pref-1-AAV-PD group were injected with PFU recombinant AAV. Two weeks later, control group was injected intraperitoneally with normal saline while other groups were injected intraperitoneally with 4.25% peritoneal dialysis fluid (PDF). Thirty days later, viscerall adipose tissue was collected and weighed. Pref-1 protein expression was measured by Western blot, and peritoneal permeability was measured by Evans blue. Cluster of differentiation 31(CD31) immunohistochemical staining was used to detect mesenteric blood vessel number, and vascular endothelial growth factor (VEGF) in serum were measured by enzyme-linked immunosorbent assay.
Pref-1 protein expression increased in pref-1-AAV-PD group. Visceral adipose expanded in PD and control-AAV-PD group while decreased in pref-1-AAV-PD group, which approves PD fluid enhance visceral adipogensis, and the process could be inhibited by Pref-1 recombinant AAV. The reduction of peritoneal vessel number and the decrease of vascular permeability as well as down-regulation of serum vascular endothelial growth factor observed in pref-1-AAV-PD group suggested peritoneal angiogenesis could be inhibited following visceral adipose tissue reduction.
Visceral adipose expands is associated with peritoneal angiogenesis in PD treatment, and prevention of visceral adipogenesis may be an alternative way to protect the validity of peritoneum. Copyright © 2019 John Wiley & Sons, Ltd.
研究表明,腹膜透析(PD)患者的内脏脂肪组织和腹膜血管生成增加。然而,内脏脂肪扩张与腹膜血管生成之间的关系尚不清楚。
构建 Pref-1(前脂肪细胞因子-1)重组腺相关病毒(AAV)和对照 AAV。将小鼠分为四组,对照组和 PD 组小鼠分别经腹腔注射 PBS,对照组-AAV-PD 组小鼠经腹腔注射斑块形成单位(PFU)对照 AAV,Pref-1-AAV-PD 组小鼠经腹腔注射 PFU 重组 AAV。2 周后,对照组小鼠经腹腔注射生理盐水,其余各组小鼠经腹腔注射 4.25%腹膜透析液(PDF)。30 天后,收集内脏脂肪组织并称重。通过 Western blot 检测 Pref-1 蛋白表达,通过 Evans 蓝检测腹膜通透性。采用 CD31 免疫组化染色检测肠系膜血管数,采用酶联免疫吸附试验检测血清血管内皮生长因子(VEGF)。
Pref-1-AAV-PD 组 Pref-1 蛋白表达增加。PD 组和对照-AAV-PD 组内脏脂肪增加,而 Pref-1-AAV-PD 组内脏脂肪减少,这表明 PD 液增强内脏脂肪生成,该过程可被 Pref-1 重组 AAV 抑制。Pref-1-AAV-PD 组腹膜血管数减少,血管通透性降低,血清血管内皮生长因子下调,提示内脏脂肪减少可抑制腹膜血管生成。
PD 治疗中内脏脂肪扩张与腹膜血管生成有关,预防内脏脂肪生成可能是保护腹膜有效性的一种替代方法。版权所有©2019 约翰威立父子公司